You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股》勁方醫藥(02595.HK)今起招股 入場費4,119.13元
專注於腫瘤、自體免疫和炎症性疾病領域生物製藥公司勁方醫藥(02595.HK)在港進行首次公開發售(IPO),計劃全球發售7,760萬股H股,香港公開發售佔10%(約776萬股),國際配售部分佔90%(約6,984萬股),發售價每股20.39元,預料集資約15.82億元。每手買賣單位200股,入場費約4,119.13元。招股期由今日(11日)起至下周二(16日)中午截止,預計於下周五(19日)掛牌上市,由中信証券擔任獨家保薦人。 按發售價每股20.39元計算,集資所得淨額約14.44億元,當中約38%及約33%分別用於核心產品GFH375及GFH925的臨床開發,約19%用於為管線中其他候選產品進行進一步開發,餘下約10%用作營運資金及其他一般企業用途。 是次IPO共引入9名基石投資者,包括RTW基金、TruMed、OrbiMed、UBS Asset Management (Singapore) Ltd.、Vivo基金、匯添富基金實體、富國實體、中信証券(06030.HK)旗下中信証券國際資本管理及清池實體,合共認購約1億美元等值股份,以發售價計涉及3,823.4萬股,佔是次發售股份約49.27%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account